Firalis - Newsletters

Home
About
Services
R&D
Products
Quality
Investors
Media
Careers
IFU APO-Easy
Copy of IFU APO-Easy
Stability APO-Easy
APO-Easy-FLS-OE02-01
APO-Easy-FLS-OE02-02
APO-Easy-FLS-OE02-03

Home
About
Services
Products
R&D
Quality
Investors
Media

Newsletters

Olink in Covid-19 R&D

Olink in Covid-19 R&D

Outstanding Olink technology offering for COVID-19 Research

06.08.2020

Biopred : Firalis innovative product

Biopred: Revolutionary approach to explore inflammatory autoimmune pathways

13.03.2020

Olink technology

Targeted protein biomarker discovery with Olink technology

08.03.2020

NextSeq 500

Identify your genomic targets with Next Generation Sequencing at Firalis

05.03.2020

Largest multiplex measurement

Accelerate your Oncology Research with the unique solution at Firalis.

04.03.2020

Ella at Firalis

Ella at Firalis for your multiparallel immunoassays

02.03.2020

Contact Firalis

Firalis Group

© Copyright 2020 all rights reserved.

The company logos, products and service marks are trademarks or registered trademarks of Firalis.

-----------------------------------------------------------------------------------------------------------------------

Information addressed to health professionals. The products presented on this site are for professional use only and, where applicable, comply with the requirements of the IVD Directive 98/79 / EC. Instructions for use must be consulted before using these products.

-----------------------------------------------------------------------------------------------------------------------

Headquarter : 17 Rue du Fort 68330 Huningue FRANCE